Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

ANGHI

  • Vultures are circling BMS as it becomes an acquisition target
  • Pfizer has launched an appeal of its record-breaking fine from the NHS
  • Sartorius has joined the European Molecular Biology Laboratory

Seregraff

  • Immunicum gets a green light to include France in its ongoing Phase II trial for metastatic renal cell carcinoma
  • uniQure is officially initiating its 3-pronged approach targeting Hemophilia B, congestive heart failure and Huntington’s disease.

Riku Heikkila

  • The National Academy of Sciences and the National Academy of Medicine don’t seem to think CRISPR editing genomes is so unethical after all
  • Though it’s unclear if that opinion affects the new report from Grand View Research, CRISPR/Cas could represent a €3.9B market by 2025

Cat or Dulce de Leche?

CdjJWcpUUAAn4Bc


Images from Ol41ka, ANGHI, Seregraff, Riku Heikkila / shutterstock.com

ADVERTISEMENT
Previous post

Welcome to Melanie and Maxime, reinforcing our Berlin team ⭐️

Next post

Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials